Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The consequence of oncomorphic TP53 mutations in ovarian cancer.

International journal of molecular sciences - 23 Sept 2013

Brachova Pavla, Thiel Kristina W, Leslie Kimberly K

Abstract excerpt

Ovarian cancer is the most lethal gynecological malignancy, with an alarmingly poor prognosis attributed to late detection and chemoresistance. Initially, most tumors respond to chemotherapy but eventually relapse due to the development of drug resistance. Currently, there are no biological markers that can be used to predict patient response to chemotherapy. However, it is clear that mutations in the tumor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Cancer-related Molecular Pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Knockout Techniques

Share to Microtubule and mitosis dynamics

Share to Mutation

Share to Ovarian Neoplasms

Share to Transcriptome

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 24065105
DOI: 10.3390/ijms140919257
PMCID: PMC3794832

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The consequence of oncomorphic TP53 mutations in ovarian cancer.PMID 24065105Read ↗

TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.Semantic proximity Read ↗

Clinical relevance of gain-of-function mutations of p53 in high-grade serous ovarian carcinoma.Semantic proximity Read ↗

TP53 mutations in epithelial ovarian cancerSemantic proximity Read ↗

Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations.Semantic proximity Read ↗

Gain-of-function p53 R175H blocks apoptosis in a precursor model of ovarian high-grade serous carcinomaSemantic proximity Read ↗

TP53 mutations and the association with platinum resistance in high grade serous ovarian carcinoma.Semantic proximity Read ↗

TP53 and ovarian cancer.Semantic proximity Read ↗

A novel ITGB8 transcript variant sustains ovarian cancer cell survival through genomic instability and altered ploidy on a mutant p53 background.Semantic proximity Read ↗

Determination of Both TP53 Mutation Status and the Amount of p53 Protein has Limited Diagnostic Importance for Patients with Ovarian Cancer.Semantic proximity Read ↗

Spectrum of TP53 Mutations in BRCA1/2 Associated High-Grade Serous Ovarian CancerSemantic proximity Read ↗

Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers.Semantic proximity Read ↗

Pontin, a new mutant p53-binding protein, promotes gain-of-function of mutant p53.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.